Lexicon Pharmaceuticals, Inc. (LXRX)
| Market Cap | 406.29M |
| Revenue (ttm) | 1.20M |
| Net Income (ttm) | -177.12M |
| Shares Out | 246.24M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,968,687 |
| Open | 1.630 |
| Previous Close | 1.630 |
| Day's Range | 1.600 - 1.690 |
| 52-Week Range | 0.920 - 3.790 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 8.00 (+384.85%) |
| Earnings Date | Apr 30, 2024 |
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. ... [Read more]
Financial Performance
In 2023, LXRX's revenue was $1.20 million, an increase of 766.19% compared to the previous year's $139,000. Losses were -$177.12 million, 73.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 384.85% from the latest price.
News
Lexicon Pharmaceuticals to Host 2024 Investor Day
Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic Peripheral Neuropathic Pain Includes Business ...
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium ...
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Commercial launch of INPEFA ® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced it has entered into a securities purchase agreement (the “purchase a...
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place Ja...
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain...
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - ...
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately i...
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place Novemb...
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Commercial launch of INPEFA ® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology communit...
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the m...
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023
Lexicon Strengthens Management Team With Two New Executives
Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon P...
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin
Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP)
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE W...
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Mr. Garner brings over 25 years of pharmaceutical industry experience Mr. Garner brings over 25 years of pharmaceutical industry experience
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25th Annual Global Investment Confe...
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development
Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its re...
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure
Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
INPEFA TM (sotagliflozin) receives FDA approval for the treatment of heart failure